Novartis AG and Molecular Partners AG will report positive top-line data from the antiviral Covid-19 treatment ensovibep on Monday seeking rapid regulatory approval worldwide.
The results of a phase II study of 407 patients who received a single intravenous dose of Ensobibep showed a 78% reduction in Covid-19-related hospitalization or emergency room visits compared to placebo. , Showed an improvement in time to clinical recovery. Said.
According to a Basel-based pharmaceutical company, Ensobibep treatment continues to maintain protection against previously identified variant of concern variants, including Omicron.
He said he would exercise that option and pay CHF 150 million ($ 163.3 million) to license ensovibep from Molecular Partners.
Accelerate manufacturing scale-up.
We also plan to first seek a rapid global regulatory permit through the US Food and Drug Administration’s Emergency Use Authorization.
If approved, ensovibep will be the first multispecific antiviral molecule for the treatment of Covid-19, Novartis said.
Write to Ed Frankle at email@example.com
Novartis seeks FDA approval for COVID-19 treatment after positive data
Source link Novartis seeks FDA approval for COVID-19 treatment after positive data
The post Novartis seeks FDA approval for COVID-19 treatment after positive data appeared first on Eminetra.